BACKGROUND AND AIMS: Angiogenesis is a novel component in inflammatory bowel disease (IBD) pathogenesis. We have previously shown that immune-nonimmune interactions through the CD40-CD40-ligand (CD40L) pathway might sustain gut inflammation, although their effect on regulating inflammation-driven angiogenesis is unknown. The present study evaluated the role of the CD40-CD40L interaction in the promotion of immune-mediated angiogenesis in IBD. METHODS: Human nonimmune cells of colonic origin-namely, human intestinal fibroblasts (HIFs) and human intestinal microvascular endothelial cells (HIMECs)-were activated with either soluble CD40L (sCD40L), or CD40(+) D1.1 cells or CD40L-activated lamina propria T (LPT) cells before measuring pro-angiogenic cytokine release. Blocking antibodies to either CD40 or CD40L were used to disrupt the CD40-CD40L interaction. The dextran sodium sulphate (DSS) model of experimental colitis in CD40 and CD40L knockout mice was established to assess whether the CD40-CD40L pathway was implicated in controlling inflammation-driven angiogenesis in vivo. RESULTS: Engagement of CD40 on HIFs promoted the release of vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and hepatocyte growth factor (HGF). LPT cells were potent inducers of pro-angiogenic cytokine secretion by HIFs. Supernatants from sCD40L-activated HIFs induced migration of HIMECs and tubule formation, both of which were inhibited by blocking antibodies to either VEGF, IL-8 or HGF. Both CD40- and CD40L-deficient mice were protected from DSS-induced colitis and displayed a significant impairment of gut inflammation-driven angiogenesis, as assessed by microvascular density. CONCLUSIONS: The CD40-CD40L pathway appears to be crucially involved in regulating inflammation-driven angiogenesis, suggesting that strategies aimed at blocking CD40-CD40L interactions might be beneficial in acute and chronic intestinal injury.
BACKGROUND AND AIMS: Angiogenesis is a novel component in inflammatory bowel disease (IBD) pathogenesis. We have previously shown that immune-nonimmune interactions through the CD40-CD40-ligand (CD40L) pathway might sustain gut inflammation, although their effect on regulating inflammation-driven angiogenesis is unknown. The present study evaluated the role of the CD40-CD40L interaction in the promotion of immune-mediated angiogenesis in IBD. METHODS:Human nonimmune cells of colonic origin-namely, human intestinal fibroblasts (HIFs) and human intestinal microvascular endothelial cells (HIMECs)-were activated with either soluble CD40L (sCD40L), or CD40(+) D1.1 cells or CD40L-activated lamina propria T (LPT) cells before measuring pro-angiogenic cytokine release. Blocking antibodies to either CD40 or CD40L were used to disrupt the CD40-CD40L interaction. The dextran sodium sulphate (DSS) model of experimental colitis in CD40 and CD40L knockout mice was established to assess whether the CD40-CD40L pathway was implicated in controlling inflammation-driven angiogenesis in vivo. RESULTS: Engagement of CD40 on HIFs promoted the release of vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and hepatocyte growth factor (HGF). LPT cells were potent inducers of pro-angiogenic cytokine secretion by HIFs. Supernatants from sCD40L-activated HIFs induced migration of HIMECs and tubule formation, both of which were inhibited by blocking antibodies to either VEGF, IL-8 or HGF. Both CD40- and CD40L-deficient mice were protected from DSS-induced colitis and displayed a significant impairment of gut inflammation-driven angiogenesis, as assessed by microvascular density. CONCLUSIONS: The CD40-CD40L pathway appears to be crucially involved in regulating inflammation-driven angiogenesis, suggesting that strategies aimed at blocking CD40-CD40L interactions might be beneficial in acute and chronic intestinal injury.
Authors: Christian F Krieglstein; Wolfgang H Cerwinka; Andrew G Sprague; F Stephen Laroux; Matthew B Grisham; Victor E Koteliansky; Norbert Senninger; D Neil Granger; Antonin R de Fougerolles Journal: J Clin Invest Date: 2002-12 Impact factor: 14.808
Authors: Florencia M Barbé-Tuana; Dagmar Klein; Hirohito Ichii; Dora M Berman; Lane Coffey; Norma S Kenyon; Camillo Ricordi; Ricardo L Pastori Journal: Diabetes Date: 2006-09 Impact factor: 9.461
Authors: David M Spencer; Geertruida M Veldman; Subhashis Banerjee; Joseph Willis; Alan D Levine Journal: Gastroenterology Date: 2002-01 Impact factor: 22.682
Authors: Marlies E J Reinders; Masayuki Sho; Stuart W Robertson; Christopher S Geehan; David M Briscoe Journal: J Immunol Date: 2003-08-01 Impact factor: 5.422
Authors: Jan Heidemann; Hitoshi Ogawa; Michael B Dwinell; Parvaneh Rafiee; Christian Maaser; Henning R Gockel; Mary F Otterson; David M Ota; Norbert Lugering; Wolfram Domschke; David G Binion Journal: J Biol Chem Date: 2002-12-20 Impact factor: 5.157
Authors: G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis Journal: Med Oncol Date: 2012-03-09 Impact factor: 3.064
Authors: M-A Jenabian; M Patel; I Kema; K Vyboh; C Kanagaratham; D Radzioch; P Thébault; R Lapointe; N Gilmore; P Ancuta; C Tremblay; J-P Routy Journal: Clin Exp Immunol Date: 2014-10 Impact factor: 4.330
Authors: Ilaria Deambrosis; Sara Lamorte; Fulvia Giaretta; Lorenzo Tei; Luigi Biancone; Benedetta Bussolati; Giovanni Camussi Journal: J Mol Med (Berl) Date: 2008-11-05 Impact factor: 4.599